Glaukos Co. (NYSE:GKOS) Shares Sold by Park Place Capital Corp

Park Place Capital Corp lessened its stake in Glaukos Co. (NYSE:GKOS) by 21.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 237 shares of the medical instruments supplier’s stock after selling 65 shares during the period. Park Place Capital Corp’s holdings in Glaukos were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in shares of Glaukos by 294.5% during the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after buying an additional 1,630,270 shares during the period. State Street Corp boosted its stake in shares of Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after buying an additional 98,109 shares during the period. Primecap Management Co. CA boosted its stake in shares of Glaukos by 2.0% during the third quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock worth $162,223,000 after buying an additional 24,370 shares during the period. Geode Capital Management LLC raised its holdings in Glaukos by 6.0% during the third quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier’s stock worth $152,722,000 after purchasing an additional 66,134 shares in the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in Glaukos by 24.0% during the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock worth $95,112,000 after purchasing an additional 155,653 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on GKOS. BTIG Research increased their price target on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and increased their price target for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Monday, December 2nd. UBS Group began coverage on shares of Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price target for the company. Finally, Stifel Nicolaus increased their price target on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $147.75.

Insider Activity

In related news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now owns 32,336 shares in the company, valued at approximately $4,656,707.36. This trade represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,603 shares of company stock worth $2,605,678 over the last ninety days. 6.40% of the stock is currently owned by insiders.

Glaukos Stock Up 0.9 %

GKOS stock opened at $161.55 on Friday. The company’s 50 day simple moving average is $146.86 and its 200-day simple moving average is $134.31. The firm has a market capitalization of $8.91 billion, a PE ratio of -53.49 and a beta of 1.04. Glaukos Co. has a 12 month low of $83.90 and a 12 month high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.50) earnings per share. Equities analysts expect that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.